IRAY TECHNOLOGY(688301) 中泰证券·2024-05-03 07:30Investment Rating - The report maintains an "Accumulate" rating for the company [1][11]. Core Views - The company achieved a revenue of 491 million yuan in Q1 2024, representing a year-on-year growth of 11.48% and a quarter-on-quarter growth of 5.14% [6][7]. - The net profit attributable to the parent company for Q1 2024 was 139 million yuan, a year-on-year increase of 1.88% [6][7]. - The company is focusing on expanding its product layout and increasing the scale of its X-ray core components business through a planned capital increase of no more than 1.45 billion yuan [11]. Financial Performance Summary - Revenue Forecasts: - 2022A: 1,549 million yuan - 2023A: 1,864 million yuan - 2024E: 2,352 million yuan - 2025E: 2,851 million yuan - 2026E: 3,406 million yuan - Year-on-year growth rates are projected at 30%, 20%, 26%, 21%, and 19% respectively [5]. - Net Profit Forecasts: - 2022A: 641 million yuan - 2023A: 607 million yuan - 2024E: 813 million yuan - 2025E: 1,025 million yuan - 2026E: 1,239 million yuan - Year-on-year growth rates are projected at 32%, -5%, 34%, 26%, and 21% respectively [5]. - Earnings Per Share (EPS): - 2024E: 6.29 yuan - 2025E: 7.97 yuan - 2026E: 10.05 yuan [5]. Industry and Product Development - The company is expanding its CT core component production, focusing on domestic production capabilities [8][10]. - The global CT detector market was valued at approximately 1.68 billion USD in 2021, with an expected annual growth rate of around 4.3% from 2022 to 2027 [8]. - The company has made significant advancements in its R&D, with 62 new intellectual property applications in 2023, including 32 invention patent applications [7][8].